New Blood Test for Pancreatic Cancer
Author Information
Author(s): C.K. Ching, J.M. Rhodes
Primary Institution: University Department of Medicine and Walton Hospital, Liverpool, UK
Hypothesis
Can an enzyme-linked peanut lectin binding assay improve the diagnosis of pancreatic cancer compared to existing tests?
Conclusion
The enzyme-linked peanut lectin assay is a reproducible and effective diagnostic tool for pancreatic cancer, with sensitivity and specificity comparable to CA19-9 radioimmunoassay.
Supporting Evidence
- The enzyme-linked peanut lectin assay showed 77% sensitivity and 83% specificity for pancreatic cancer.
- Combining the peanut lectin assay with CA19-9 improved sensitivity to 85%.
- Patients with metastatic disease had significantly higher peanut lectin binding activity than those with localized disease.
Takeaway
Doctors can use a new blood test to help find pancreatic cancer, which is usually hard to diagnose. This test works well and is easy to do.
Methodology
The study evaluated serum samples from patients with pancreatic cancer and various controls using an enzyme-linked lectin assay and compared results with CA19-9 and CEA assays.
Potential Biases
Potential bias from the selection of control groups and the reliance on serum markers that may overlap with other conditions.
Limitations
The study did not achieve better sensitivity without reducing specificity, and false positives may occur in other cancers.
Participant Demographics
53 patients with pancreatic cancer (mean age 63, 27 males, 26 females) and 154 controls with various conditions.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website